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Response By the Authors:
We thank Dr Czartoski and Dr. Becker for 
their interest in our report (1). Although cere-
brovascular complications are frequent in 
pneumococcal meningitis, with an incidence 
of more than 20% for arterial complications 
(2), no study has systematically character-
ized these complications. In this context the 
suggestion of an early vasculitic process 
being distinct from a more chronic vascular 
inflammation seems hypothetical. In our 
 report, vasculitis was certainly an early 
 complication of pneumococcal meningitis. 
The patient developed focal neurological 
symptoms 3 days after the onset of menin-
gitis, with two hypodensities in the right 
 posterior arm of the internal capsula. The 
prolonged course of vascular inflammation 
and the relapse after steroid reduction 
that we observed may be caused by the 
delayed initiation of the immunosuppressive 
treatment.
We agree that the occurrence of persistent 
postinfectious vasculitis might be related to 
a host susceptibility, but the nature of the in-
fectious pathogen is certainly also critical. It 
is noteworthy that vasculitic complications 
are observed more frequently in pneumococ-
cal meningitis (3) and that the benefit of ste-
roids seems to be greatest in patients with 
pneumoccocal disease (4).
Neurological complications in pneumo-
coccal meningitis are extremely various and 
difficult to predict. A critical issue is to iden-
tify patients susceptible to development of 
severe vascular complications and who 
would benefit from aggressive and pro-
longed immunosuppression. Leppert et al. 
(5) previously reported that cerebrospinal 
fluid levels of matrix metalloproteinase-9 
(MMP-9) were higher in patients with long-
term neurological deficits. MMPs play a key 
role in the extravasation of inflammatory 
cells in the central nervous system and may 
be directly implicated in the pathophysiol-
ogy of meningitic vasculitis. In our case re-
port, the patient clinical evolution and the 
vascular process correlated with MMP-9 lev-
els. Thus, MMP-9 could be a marker of vas-
cular inflammation and help to identify and 
monitor patients who could benefit from 
aggressive and prolonged immunosuppres-
sion. Further studies are needed to confirm 
this hypothesis.
References
1. Pugin D, Copin JC, Goodyear MC, Landis T, 
Gasche Y. Persisting vasculitis after pneumo-
coccal meningitis. Neurocrit Care 2006; 4:
237–240.
2. Kastenbauer S, Pfister HW. Pneumococcal 
meningitis in adults: spectrum of complica-
tions and prognostic factors in a series of 87 
cases. Brain 2003;126:1015–1025.
3. van de Beek D, de Gans J, Spanjaard L, Weis-
felt M, Reitsma JB, Vermeulen M. Clinical 
features and prognostic factors in adults with 
bacterial meningitis. N Engl J Med 
2004;351:1849–1859.
4. de Gans J, van de Beek D. Dexamethasone in 
adults with bacterial meningitis. N Engl J Med 
2002;347:1549–1556.
5. Leppert D, Leib SL, Grygar C, Miller KM, Schaad 
UB, Hollander GA. Matrix metalloproteinase 
(MMP)-8 and MMP-9 in cerebrospinal fluid dur-
ing bacterial meningitis: association with blood-
brain barrier damage and neurological sequelae. 
Clin Infect Dis 2000;31:80–84.
Letter to the Editor
*Correspondence and reprint 
requests to:
Yvan Gasche
Division of Critical Care 
Medicine
Geneva University Hospital
24, Rue Micheli-du-Crest,
CH-1211,
Geneva, Switzerland.
E-mail: 
yvan.gasche@medecine.unige.ch
